Timmermans J, Amighi K, Puigdevall J, Baltes E, Moës A J
UCB S.A. Pharma Sector, Research and Development, Toxicological Research Department Chemin du Foriest, Braine-l'Alleud, Belgium.
Drug Dev Ind Pharm. 1998 Jun;24(6):517-25. doi: 10.3109/03639049809085652.
Sustained-release (SR) dosage forms consisting of pellets coated with different pH-sensitive film layers, previously optimized in vitro with regard to pH independence of their drug release characteristics, were evaluated in vivo after single administration to Beagle dogs. In vivo performances were compared to those of a nonoptimized SR matrix tablet and a reference instant release (IR) capsule, in terms of the observed plasma pharmacokinetic profiles for the parent drug (ucb 11056) and its primary metabolite (ucb 26201), the bioavailability results, and the drug tolerance data. All SR dosage forms were seen to be effective in prolonging the relatively short biological half-life of the compound and in reducing the incidence of concentration-related side-effects, e.g., emesis, and of behavioral symptoms, e.g., restlessness, discomfort, and indisposition. The film-coated SR pellets offer a number of advantages over the monolithic SR matrix system in terms of a drug delivery pattern less dependent on pH changes in the gastrointestinal (GI) tract, a higher flexibility for adjusting and controlling the pharmacokinetic profiles, and a consequently more efficient approach for keeping all concentration-related side-effects under control.
由包有不同pH敏感膜层的微丸组成的缓释(SR)剂型,此前已在体外针对其药物释放特性的pH独立性进行了优化,在对比格犬单次给药后进行了体内评估。就母体药物(ucb 11056)及其主要代谢物(ucb 26201)的血浆药代动力学曲线、生物利用度结果和药物耐受性数据而言,将体内性能与未优化的SR基质片剂和参比速释(IR)胶囊的性能进行了比较。所有SR剂型在延长该化合物相对较短的生物半衰期以及减少浓度相关副作用(如呕吐)和行为症状(如烦躁、不适和身体不适)的发生率方面均被证明是有效的。与整体式SR基质系统相比,薄膜包衣SR微丸在药物递送模式上较少依赖胃肠道(GI)中的pH变化、在调节和控制药代动力学曲线方面具有更高的灵活性,因此是一种更有效的方法来控制所有与浓度相关的副作用。